Stock Events

Stock Events

Novakand Pharma AB 

€0
2
-€0-50% Friday 07:07

Statistics

Day High
0
Day Low
0
52W High
0.16
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
12,118.6
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22MayExpected
Q3 2024
Next
0.04
0.38
0.71
1.04
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-12.57MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 3EE0.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Astrazeneca
AZN.ST
Mkt Cap2.7T
AstraZeneca operates in the biopharmaceutical sector, focusing on the discovery, development, and commercialization of prescription medicines, directly competing with Kancera's therapeutic areas.
Oncopeptides AB
ONCO.ST
Mkt Cap531.7M
Oncology Venture A/S focuses on the development of drugs for the treatment of cancer, making it a direct competitor to Kancera in the oncology research and development field.
Mendus AB
IMMU.ST
Mkt Cap305.8M
Immunicum AB develops immunotherapies for the treatment of cancer, competing with Kancera's cancer-focused research and therapies.
KDventures AB
KDEV.ST
Mkt Cap273.59M
Karolinska Development AB invests in life science companies, potentially competing with Kancera by funding rival projects in cancer and disease treatment research.
Xbrane Biopharma AB
XBRANE.ST
Mkt Cap196.16M
Xbrane Biopharma AB specializes in biosimilars and long-acting injectables, indirectly competing with Kancera by offering alternative cancer treatment solutions.

About

Novakand Pharma AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase II study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. The company was formerly known as Kancera AB (publ) and changed its name to Novakand Pharma AB (publ) in September 2025. Novakand Pharma AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Show more...
CEO
Mr. Peter Selin
Employees
5
Country
Germany
ISIN
SE0015658570
WKN
000A2QQQ4

Listings

STU
DE
3EE0.STU
ST
SE
NOVKAN.ST

0 Comments

Share your thoughts

FAQ

What is Novakand Pharma AB stock price today?▼
The current price of 3EE0.F is €0 EUR — it has decreased by -50% in the past 24 hours. Watch Novakand Pharma AB stock price performance more closely on the chart.
What is Novakand Pharma AB stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Novakand Pharma AB stocks are traded under the ticker 3EE0.F.
Is Novakand Pharma AB stock price growing?▼
3EE0.F stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Novakand Pharma AB has showed a -99.89% decrease.
What is Novakand Pharma AB market cap?▼
Today Novakand Pharma AB has the market capitalization of 12,118.6
When is the next Novakand Pharma AB earnings date?▼
Novakand Pharma AB is going to release the next earnings report on May 22, 2026.
What is Novakand Pharma AB revenue for the last year?▼
Novakand Pharma AB revenue for the last year amounts to 0 EUR.
What is Novakand Pharma AB net income for the last year?▼
3EE0.F net income for the last year is -12.57M EUR.
How many employees does Novakand Pharma AB have?▼
As of April 29, 2026, the company has 5 employees.
In which sector is Novakand Pharma AB located?▼
Novakand Pharma AB operates in the Health & Wellness sector.
When did Novakand Pharma AB complete a stock split?▼
The last stock split for Novakand Pharma AB was on February 24, 2021 with a ratio of 1:10.
Where is Novakand Pharma AB headquartered?▼
Novakand Pharma AB is headquartered in Solna, Germany.